About the Study: Is neonatal medical male circumcision (NMC) associated with child autism spectrum disorder (ASD) or autism-related traits and behaviors? In this cohort study of 2771 male children from 14 cohort sites in the Environmental Influences on Child Health Outcomes (ECHO) Cohort, NMC was not associated with ASD diagnosis or autism-related traits and behaviors. These findings were robust after stratification by geographic region, preterm birth, and neonatal intensive care unit admission status; additionally, acetaminophen use during the procedure or in the neonatal period was uncommon (<5%). This study found no evidence that NMC is associated with an increased risk of ASD, which may provide reassurance for families who are considering or have elected NMC for their child.

To better support the health of children, school nurse specialist Erin Maughan and the American Academy of Nursing provide a pathway and policy recommendations for redesigning health care to focus on a holistic child approach using nurses’ unique perspect

Lindsay A. Farrer, PhD, chief of biomedical genetics at Boston University Chobanian & Avedisian School of Medicine, has been selected as the recipient of a 3-year, $450,000 Zenith Fellows Award from the Alzheimer’s Association for his project, “Genes to AD Therapy: A Roadmap for Personalized Medicine.” Zenith Fellows Awards are among the most prestigious in Alzheimer's research worldwide.

VCU Massey Comprehensive Cancer Center was recently awarded a $2.7 million Worta McCaskill-Stevens K12 grant from the National Institutes of Health (NIH). The five-year grant will allow Massey to mentor promising, multidisciplinary, early-stage clinical investigators in the conception, development, and implementation of innovative cancer prevention and control studies designed to optimize participation by cancer survivors and individuals most at risk for cancer throughout Virginia.VCU Massey Comprehensive Cancer Center was recently awarded a $2.7 million Worta McCaskill-Stevens K12 grant from the National Institutes of Health (NIH). The five-year grant will allow Massey to mentor promising, multidisciplinary, early-stage clinical investigators in the conception, development, and implementation of innovative cancer prevention and control studies designed to optimize participation by cancer survivors and individuals most at risk for cancer throughout Virginia.

Insilico Medicine (“Insilico”, HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced that ISM8969/HT-001, an innovative oral NLRP3 inhibitor co-developed with Hygtia Therapeutics, has received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) of China for the treatment of Parkinson's disease. Following the announcement of first-in-human dosing in Australia under the Phase I study in June 2026, this approval marks the official launch of parallel clinical evaluations in China and Australia. The clinical trial aims to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ISM8969/HT-001 in healthy subjects and preliminary efficacy of ISM8969/HT-001 in patients with Parkinson's disease, establishing a foundation for its subsequent clinical development.